Generate Biomedicines Statistics
Total Valuation
GENB has a market cap or net worth of $1.64 billion. The enterprise value is $1.25 billion.
| Market Cap | 1.64B |
| Enterprise Value | 1.25B |
Important Dates
The next estimated earnings date is Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GENB has 128.35 million shares outstanding.
| Current Share Class | 128.35M |
| Shares Outstanding | 128.35M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +97.68% |
| Owned by Insiders (%) | 4.07% |
| Owned by Institutions (%) | 29.18% |
| Float | 60.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 60.68 |
| Forward PS | 79.75 |
| PB Ratio | 3.52 |
| P/TBV Ratio | 3.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 45.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.30, with a Debt / Equity ratio of 0.14.
| Current Ratio | 8.30 |
| Quick Ratio | 8.08 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -328.93 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -51.97% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $84,881 |
| Profits Per Employee | -$861,135 |
| Employee Count | 312 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GENB has paid $144,000 in taxes.
| Income Tax | 144,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 15.41 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 36.75 |
| Average Volume (20 Days) | 1,129,667 |
Short Selling Information
The latest short interest is 7.42 million, so 5.78% of the outstanding shares have been sold short.
| Short Interest | 7.42M |
| Short Previous Month | 7.18M |
| Short % of Shares Out | 5.78% |
| Short % of Float | 12.27% |
| Short Ratio (days to cover) | 6.27 |
Income Statement
In the last 12 months, GENB had revenue of $26.48 million and -$268.67 million in losses. Loss per share was -$3.28.
| Revenue | 26.48M |
| Gross Profit | -213.80M |
| Operating Income | -262.49M |
| Pretax Income | -250.73M |
| Net Income | -268.67M |
| EBITDA | -249.55M |
| EBIT | -262.49M |
| Loss Per Share | -$3.28 |
Balance Sheet
The company has $457.42 million in cash and $62.63 million in debt, with a net cash position of $394.79 million or $3.08 per share.
| Cash & Cash Equivalents | 457.42M |
| Total Debt | 62.63M |
| Net Cash | 394.79M |
| Net Cash Per Share | $3.08 |
| Equity (Book Value) | 456.05M |
| Book Value Per Share | 3.56 |
| Working Capital | 413.62M |
Cash Flow
In the last 12 months, operating cash flow was -$237.02 million and capital expenditures -$7.32 million, giving a free cash flow of -$244.35 million.
| Operating Cash Flow | -237.02M |
| Capital Expenditures | -7.32M |
| Depreciation & Amortization | 12.94M |
| Net Borrowing | -5.21M |
| Free Cash Flow | -244.35M |
| FCF Per Share | -$1.90 |
Margins
| Gross Margin | n/a |
| Operating Margin | -991.15% |
| Pretax Margin | -946.77% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GENB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -16.72% |
| FCF Yield | -15.21% |
Analyst Forecast
The average price target for GENB is $27.00, which is 110.77% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $27.00 |
| Price Target Difference | 110.77% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 42.47% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GENB has an Altman Z-Score of 6.99 and a Piotroski F-Score of 1.
| Altman Z-Score | 6.99 |
| Piotroski F-Score | 1 |